Cargando…

P1412: UNCOUPLING INK4 PROTEINS FROM CDK4/CDK6 IN HEMATOPOIETIC STEM CELLS

Detalles Bibliográficos
Autores principales:	Schirripa, A., Prchal-Murphy, M., Grausenburger, R., Kollmann, K., Sexl, V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429560/ http://dx.doi.org/10.1097/01.HS9.0000848508.28508.68

Ejemplares similares

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

P1407: CDK6 IN HEMATOPOIETIC STEM CELLS: MORE THAN A CELL CYCLE KINASE
por: Mayer, I., et al.
Publicado: (2022)

CDK6 and p16(INK4A) in lymphoid malignancies
por: Kollmann, Karoline, et al.
Publicado: (2013)

CDK6 Degradation Is Counteracted by p16(INK4A) and p18(INK4C) in AML
por: Schmalzbauer, Belinda S., et al.
Publicado: (2022)

c-JUN prevents methylation of p16INK4a (and Cdk6): the villain turned bodyguard
por: Kollmann, Karoline, et al.
Publicado: (2011)

CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
por: Scheiblecker, Lisa, et al.
Publicado: (2020)

The role of CDK6 in cancer
por: Nebenfuehr, Sofie, et al.
Publicado: (2020)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

P1310: A ROBUST APPROACH FOR THE GENERATION OF FUNCTIONAL HEMATOPOIETIC PROGENITOR CELL LINES TO MODEL LEUKEMIC TRANSFORMATION
por: Doma, E., et al.
Publicado: (2022)

CDK6 Inhibition: A Novel Approach in AML Management
por: Uras, Iris Z., et al.
Publicado: (2020)

Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA
por: Perez, Marco, et al.
Publicado: (2015)

Cdk6 contributes to cytoskeletal stability in erythroid cells
por: Uras, Iris Z., et al.
Publicado: (2017)

Mutation testing in melanoma families: INK4A, CDK4 and INK4D
por: Newton Bishop, J A, et al.
Publicado: (1999)

Cdk6: At the interface of Rb and p53
por: Nebenfuehr, Sofie, et al.
Publicado: (2018)

INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors
por: Li, Qing, et al.
Publicado: (2022)

T Cell-Intrinsic CDK6 Is Dispensable for Anti-Viral and Anti-Tumor Responses In Vivo
por: Klein, Klara, et al.
Publicado: (2021)

The Effect of CDK6 Expression on DNA Methylation and DNMT3B Regulation
por: Heller, Gerwin, et al.
Publicado: (2020)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

Simulation of Different Truncated p16(INK4a) Forms and In Silico Study of Interaction with Cdk4
por: Fahham, Najmeh, et al.
Publicado: (2008)

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
por: Pack, Lindsey R., et al.
Publicado: (2021)

JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21
por: Colleoni, B, et al.
Publicado: (2017)

Lineage specific composition of cyclin D–CDK4/CDK6–p27 complexes reveals distinct functions of CDK4, CDK6 and individual D‐type cyclins in differentiating cells of embryonic origin
por: Bryja, V., et al.
Publicado: (2008)

An Opposite Effect of the CDK Inhibitor, p18(INK4c) on Embryonic Stem Cells Compared with Tumor and Adult Stem Cells
por: Li, Yanxin, et al.
Publicado: (2012)

The transcriptome of CDK4/6 inhibition
por: Knudsen, Erik S., et al.
Publicado: (2017)

CDK4 T172 Phosphorylation Is Central in a CDK7-Dependent Bidirectional CDK4/CDK2 Interplay Mediated by p21 Phosphorylation at the Restriction Point
por: Bisteau, Xavier, et al.
Publicado: (2013)

CDK6 Levels Regulate Quiescence Exit in Human Hematopoietic Stem Cells
por: Laurenti, Elisa, et al.
Publicado: (2015)

Regulation of CDK4
por: Bockstaele, Laurence, et al.
Publicado: (2006)

Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
por: Wu, Xuewei, et al.
Publicado: (2021)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
por: Sun, Ran, et al.
Publicado: (2022)

Unexpected Outcomes of CDK4/6 Inhibition
por: Choi, Yoon Jong, et al.
Publicado: (2013)

Targeting CDK4/6 for Anticancer Therapy
por: Qi, Jiating, et al.
Publicado: (2022)

CDK 4/6 inhibitors for the treatment of meningioma
por: Young, Jacob S., et al.
Publicado: (2022)

P16(INK4a) Regulates ROS-Related Autophagy and CDK4/6-Mediated Proliferation: A New Target of Myocardial Regeneration Therapy
por: Sun, Jiateng, et al.
Publicado: (2023)

Loss of p16(INK4A) stimulates aberrant mitochondrial biogenesis through a CDK4/Rb-independent pathway
por: Tyagi, Ethika, et al.
Publicado: (2017)

A kinase-independent role for CDK8 in BCR-ABL1(+) leukemia
por: Menzl, Ingeborg, et al.
Publicado: (2019)

CDK8-Novel Therapeutic Opportunities
por: Menzl, Ingeborg, et al.
Publicado: (2019)

p18 inhibits reprogramming through inactivation of Cdk4/6
por: Zhu, Shaohua, et al.
Publicado: (2016)

p16(INK4A)-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases
por: Ni, Jing, et al.
Publicado: (2022)

Cdk2 and Cdk4 cooperatively control the expression of Cdc2
por: Berthet, Cyril, et al.
Publicado: (2006)

TARGETING CANCER STEM CELLS WITH A CDK2 INHIBITOR IN GLIOBLASTOMA
por: Mahmnoudian, Elham, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oo7mqip25sos7v62lff6rapj6g